Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 16, 2025 07:00 ET | Source: Supernus Pharmaceuticals, Inc.; Sage Therapeutics, Inc.

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.Strengthens Supernus’ leading presence in neuropsychiatric conditions with...
May 29, 2025 08:30 ET | Source: Supernus Pharmaceuticals, Inc.

Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals

ROCKVILLE, Md., May 29, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals is expanding its partnership with TV personality and sports reporter Jay Glazer in a new content series featuring his wife,...
May 28, 2025 16:05 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Announces Paragraph IV ANDA Filings for Qelbree®

ROCKVILLE, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
May 28, 2025 16:05 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus to Participate in the 2025 Jefferies Global Healthcare Conference

ROCKVILLE, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
May 20, 2025 08:30 ET | Source: Supernus Pharmaceuticals, Inc.

Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being ‘Ms. Represented’ in First-of-its-Kind Campaign with Supernus Pharmaceuticals

Females with ADHD frequently present with inattentive symptoms, which can be more difficult to recognize than the hyperactive and impulsive symptoms more often seen in malesBoys are two times more...
May 06, 2025 16:08 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Announces First Quarter 2025 Financial Results

First quarter 2025 net sales of Qelbree® increased 44% to $64.7 million, compared to the same period in 2024.First quarter 2025 net sales of GOCOVRI® increased 16% to $30.7 million, compared to the...
April 23, 2025 17:14 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025

ROCKVILLE, Md., April 23, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
March 04, 2025 16:30 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus to Participate in Two Upcoming Investor Conferences

ROCKVILLE, Md., March 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
February 27, 2025 08:30 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus to Participate in the TD Cowen 45th Annual Health Care Conference

ROCKVILLE, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
February 25, 2025 16:01 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Announces Fourth Quarter and Full Year 2024 Financial Results

Fourth quarter 2024 net sales of Qelbree® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of Qelbree increased 72% to $241.3 million, compared to full...